Unlike lymphoma and leukaemia cells, carcinoma and sarcoma cells which have gained access to the blood do not circulate but are generally arrested in the first capillary bed encountered. The major sites for metastasis are therefore determined by the venous drainage of the primary tumour. If this is vena caval lung and bone metastases (via vertebral venous shunts) predominate, while the liver is the primary site for metastasis of portal draining tumours. Cells released from primary or secondary lung tumours gain direct access to the arterial circulation and are trapped in all of the different organs of the body in proportion to the blood flow to the individual organs. However, the probability that such a trapped cancer cell develops into a metastasis varies by a factor of 104 between adrenal (highest) and skeletal muscle and gut (lowest) for the rat sarcomas and carcinomas studied. That tissue specific host factors are responsible for this preference is suggested by the finding that tissue injury, such as an incision in skin, an anastamosis of the intestine or mechanical trauma to kidney or liver markedly facilitates metastasis. Growth factors released at sites of injury, particularly coming from infiltrating macrophages allow isolated cancer cells delivered via the blood to grow into macroscopic lesions. In the absence of exogenous stimulating factors, single cells remain dormant and eventually die. The work of this laboratory is based on the concept that the driving force of the metastatic process is created by regulatory genomic disturbances in a small population of cells within the primary tumour and that the success or failure of such cells to form a deposit in distant organs is not random but dictated by interactions between the tumour Ltd., 1987 Br. J. Cancer (1987 JOINT MEETING OF THE BACR AND THE ACP and qualitative differences in the cells' proteins, and these in turn reflect differences in the populations of the mRNAs in the cells. Thus, phenotypic changes associated with the emergence of cells with metastatic potential should be accompanied by changes in the relative abundances of specific mRNAs. Molecular cloning techniques allow the isolation of cDNA probes homologous to previously uncharacterized mRNAs that are associated with a particular cellular phenotype. We therefore constructed recombinant plasmid cDNA libraries representing the poly(A)' RNAs from normal colonic mucosa and from a liver metastasis from a colonic adenocarcinoma. Screening of these libraries with 32P-cDNAs transcribed from poly(A)' RNAs from specimens of 3 normal colonic mucosae, 3 adenocarcinomas and 3 liver metastases identified 34 recombinants that were homologous to RNAs that differed significantly in abundance between normal and neoplastic colon or between primary tumours and metastases.
Unlike lymphoma and leukaemia cells, carcinoma and sarcoma cells which have gained access to the blood do not circulate but are generally arrested in the first capillary bed encountered. The major sites for metastasis are therefore determined by the venous drainage of the primary tumour. If this is vena caval lung and bone metastases (via vertebral venous shunts) predominate, while the liver is the primary site for metastasis of portal draining tumours. Cells released from primary or secondary lung tumours gain direct access to the arterial circulation and are trapped in all of the different organs of the body in proportion to the blood flow to the individual organs. However, the probability that such a trapped cancer cell develops into a metastasis varies by a factor of 104 between adrenal (highest) and skeletal muscle and gut (lowest) for the rat sarcomas and carcinomas studied. That tissue specific host factors are responsible for this preference is suggested by the finding that tissue injury, such as an incision in skin, an anastamosis of the intestine or mechanical trauma to kidney or liver markedly facilitates metastasis. Growth factors released at sites of injury, particularly coming from infiltrating macrophages allow isolated cancer cells delivered via the blood to grow into macroscopic lesions. In the absence of exogenous stimulating factors, single cells remain dormant and eventually die. The work of this laboratory is based on the concept that the driving force of the metastatic process is created by regulatory genomic disturbances in a small population of cells within the primary tumour and that the success or failure of such cells to form a deposit in distant organs is not random but dictated by interactions between the tumour *Enquiries to the BACR Secretariat, c/o Institute of Biology, 20 Queensberry Place, London SW7 2DZ, UK. tThis issue pp. 91-95.
IReprints of these abstracts are not available -Ed. cells showering out from the primary and metabolic conditions encountered in the microenvironment or other organs in the body where they lodge. Superimposed on such local interactions are systemic effects exerted by the immune and endocrine systems, the magnitude of which depends on the type and quantity of exposed antigens and receptors on the disseminating tumour cells as well as on the constitutional vigour of the host. We have adopted a number of different approaches in an attempt to identify the gene or genes involved in metastases. The first approach has been to introduce a defined gene with known oncogenic potential into a previously non-metastatic cell and to observe for phenotypic change. This involved transfections of the cHarvey ras oncogene into a non-tumorigenic non-metastatic cell. A second approach involves transfection of total genomic DNA from metastatic to non-metastatic cells.
Finally we have examined whether treatment of weakly metastatic cells with agents known to influence tumour progression and gene expression (e.g. tetra-phorbol acetate or 5-azacytidine) can affect metastatic capability. We shall present results which indicate that, while successful incorporation and expression of the activated c-Ha-ras oncogene did not induce non-metastatic 3T3 derived fibrosarcoma cells to become spontaneously metastatic, transfection of the same cell type with DNA from highly metastatic human and animal cell lines did markedly augment their spontaneous metastatic capability and their lung colony forming potential and induce them to form deposits in many extra pulmonary sites. We have also found that treatment of some tumour cell lines with azacytidine and TPA markedly increases their metastatic behaviour after subcutaneous inoculation and, as several cell divisions must have occurred in producing the subcutaneous tumour before the cells disseminated, we consider the change of phenotype to be heritable and probably caused by alterations in gene expression. These results suggest that components of the metastatic phenotype are heritable, highly conserved in evolution and can be conferred on previously non-metastatic tumour cells by transfer of genomic DNA. However the process is so complex that there is need for caution in interpretation and points requiring further critical evaluation will be discussed.
Messenger RNAs putatively associated with progression and metastasis of colorectal cancers and qualitative differences in the cells' proteins, and these in turn reflect differences in the populations of the mRNAs in the cells. Thus, phenotypic changes associated with the emergence of cells with metastatic potential should be accompanied by changes in the relative abundances of specific mRNAs. Molecular cloning techniques allow the isolation of cDNA probes homologous to previously uncharacterized mRNAs that are associated with a particular cellular phenotype. We therefore constructed recombinant plasmid cDNA libraries representing the poly(A)' RNAs from normal colonic mucosa and from a liver metastasis from a colonic adenocarcinoma. Screening of these libraries with 32P-cDNAs transcribed from poly(A)' RNAs from specimens of 3 normal colonic mucosae, 3 adenocarcinomas and 3 liver metastases identified 34 recombinants that were homologous to RNAs that differed significantly in abundance between normal and neoplastic colon or between primary tumours and metastases.
Five of these recombinants and their homologous RNAs have been characterized further by Southern and Northern blot and RNA dot-blot analyses. These cDNAs, and other isolated from the libraries, may prove to be of use both as diagnostic tools and for defining phenotypic changes associated with tumour progression and metastasis. Cellular proliferation constitutes a vital part of the metastatic process such that understanding mechanisms involved in the control of mitogenesis may provide insight into possible approaches to the control of secondary tumour growth. Binding of extracellular mitogenic ligands to specific receptors leads to the initiation of active messenger molecules which mediate transduction of the proliferation signal from the cell surface to the nucleus. Recent interest has focused on the possibility that the rapid enhancement of expression of c-/os and c-myc mRNA plays a role in transduction of the mitogenic signal in the nucleus.
Using two tumour models, a murine reticulum cell sarcoma and a series of melanoma variants (human and murine) of defined metastatic activity, we have begun to examine the response of malignant tumours to a series of mitogenic factors in terms of cellular proliferation, generation of second messenger molecules and expression of the cellular oncogenes c-fos and c-myc. Metastatic behaviour of neoplastic cells treated in this fashion has been assessed by subsequent injection into immunocompetent, syngeneic mice or immunoincompetent, athymic mice. Early results show that some of the agents which elicit mitogenic responses in normal cells inhibit proliferation, and decrease the metastatic capacity, of their malignant counterparts. Differences also may exist in the response of high and low metastatic lines, derived from a common parent, to similar treatments. The possibility that these variations in growth regulation may provide an approach to therapy currently is under investigation.
Selection and characterization of metastatic variants in human melanoma xenografts J.F. Dore, S. Bertrand & M. Bailly INSERM U218, Centre Leon BNrard, 28 rue Lainnec, 69373 LYon Cedex 08, France.
The selection of human melanoma variants and clones with increased metastatic abilities was attempted by xenografting human melanoma cell lines in athymic nude mice and in immunosuppressed new-born rats.
Subcutaneous transplantation in a nude mouse of a human melanoma metastatic nodule resulted in a subcutaneously growing tumour (NTT) and in spontaneous lung (NTP) and lymph node (NTG) metastases (Neulat-Duga et al., Invasion Metast., 4, 209, 1984) . NTT, NTP and NTG cells were first maintained in vivo by subcutaneous passages in nude mice and then cultured in vitro as cell lines. Cytogenetic studies of the in vivo passaged cells showed that the 3 tumour lines differed in their modal chromosome number. 15 markers were identified, including several common to all 3 lines; one of these, derived from chromosome 7 and containing an HSR, was found with a higher frequency in metastatic tumour lines. In addition, 2 markers derived from chromosome I were both present in NTT cells but mutually exclusive in NTP and NTG cells.
Thus, all 3 tumour lines have a common origin and metastases in the nude mouse resulted from a selection among cell populations. Following 15 in vitro passages, NTP cells were injected s.c. in nude mice: serial transplantation was accompanied by an increase in metastatic ability of tumour cells.
Human melanoma cell lines, tumorigenic but not metastatic in nude mice, were xenografted to ATS immunosuppressed new-born rats. 3 weeks after s.c. injection of 106 cells, nearly all rats developed tumours and a proportion of them lung and lymph node metastases. Agar cloning of M4Beu line showed that it is heterogeneous and contains poorly tumorigenic but highly metastatic cells.
The generation of metastatic mosaicism in B16 murine melanoma
To deepen our understanding of the mechanism and genetic control of mammalian excision repair it is essential to identify the genes and proteins involved. To this aim we have adopted several strategies. One of the most straightforward approaches relies on the 'correction' of repair defective mutant cells by DNA mediated transfer of the normal gene, recruited from genomic DNA of a repair competent cell line. This strategy has been successful using several CHO-mutants, but has failed thus far for xeroderma pigmentosum (XP) cells. We have found that in contrast to (CHO) Chinese hamster ovary DNA repair mutants-SV40 transformed XP-fibroblasts are practically unsuited for genomic DNA transfections because of the limited amounts of exogenous DNA incorporated by these (and other human) cells.
Using a representative of CHO complementation group 2 we have cloned the human excision repair gene ERCC-J. The status of the characterization of this gene and its product will be reported. As steps towards the isolation of ERCC-3 (complementation group 3) and ERCC-6 (group 6) genes we have generated primary and secondary transformants in transfection experiments of human DNA to excision deficient CHO mutants 27-1 (Dr R. Wood) and . The isolation of the ERCC-3 gene from cosmid libraries is in progress.
As reported (van Duin et al., Cell, 44, 913, 1986) Chinese hamster ovary cell line which exhibit hypersensitivity to DNA damaging agents. We currently have over 20 such mutants, of which 14 are under detailed investigation. Of these, 5 (designated MMC-1 to -5) were isolated on the basis of sensitivity to mitomycin C (MMC), 2 as sensitive to bleomycin (designated BLM-1 and -2), 6 sensitive to MMS (MMS-1 to -6) and 1 adriamycin-sensitive (ADR-1). Mutants MMC-I to -5 are 4-to 7-fold hypersensitive to MMC, as judged by D37 values, and vary in their crosssensitivities to other DNA damaging agents. Using alkaline elution to study the induction and repair of DNA interstrand cross-links following exposure to MMC, we have shown that MMC-4 and, more particularly, MMC-5 cells accumulate higher levels of DNA cross-links than do CHO-K I cells, but repair this damage normally. In contrast, MMC-2 cells (which are 10-fold cross-sensitive to UV light) are defective in the repair of cross-links. Mutants BLM-1 and -2, which are 7-and 14-fold sensitive to bleomycin respectively, differ markedly in their response to bleomycin treatment. BLM-I cells receive equivalent levels of DNA strand breaks to wild-type cells and are proficient in DNA repair. In contrast, BLM-2 cells (which are 2-fold crosssensitive to X-rays) not only accumulate higher levels of both single-and double-strand DNA breaks than parental cells, but also repair both forms of lesion with reduced efficiency.
ADR-1 cells accumulate more DNA strand breaks following adriamycin treatment but repair this damage with normal efficiency. In this case breaks are protein-concealed, a characteristic of topoisomerase IT-dependent scissions.
By an analysis of the drug sensitivity of cell hybrids, we have shown that the MCC, bleomycin and adriamycinsensitive mutants are all phenotypically recessive, and represent 7 different complementation groups. Only MMC-1 and -5 are genetically identical. Complementation analysis with the MSS sensitive lines is in progress.
Analysis of spontaneous mutation frequencies in the MMC and MMS sensitive lines reveals several alterations from wild-type. and show respectively a 10-fold elevated and a 2-fold reduced mutation frequency to thioguanine resistance. Of the MMS sensitive lines, MMS-1, MMS-2 and MMS-5 have a mutator phenotype, while MSS-4 is hypomutable. Differences also exist in the frequency of drug-induced mutations in these lines.
Following DNA transfection with a human gene bank, we have isolated drug-resistant derivatives of MMC-4 and BLM-2 that contain integrated human DNA sequences. (Human Genet., 74, 107, 1986) showed that cells from 4 patients with TTD had a molecular defect in DNA repair, which was in the same comple- Acta., 823, 111, 1985) which include 06-nBug, and 04-nBuT in addition to sec-butyl adducts arising from a rearrangement of the butyl group (Saffhill, Carcinogenesis, 5, 621, 1984 (RTI 12) . Forward mutations at the hypoxanthine guanine phosphoribosyl transferase locus (HGPRT) were selected following exposure to 10 ig ml-1 6-thioguanine. Induced mutation frequencies were compared following exposure to equitoxic and equimolar concentrations of ethyl methane sulphonate (EMS). (Table) . The induction of rat brain gliomas by transplacental treatment with ethylnitrosourea (ENU) has proved to be a good model for studying the development of tumours (Roscoe & Claisse, Nature, 262, 314, 1976) . We have looked at oncogene expression in the cloned glioma cell line, A15A5 and a cloned line from a normal adult rat brain, ARBO C9, using Northern blot analysis. Hybridisation with a human genomic N-ras probe revealed increased expression of 2 species of mRNA, 3.8 and 3.4kb, in the glioma cells. There was no expression of Ki-or Ha-ras nor in this system, of c-cis or epidermal growth factor receptor-related mRNAs which have been found in several human neural tumours.
Hybridisation with a v-myc probe gave bands at 2.4 and 2.7kb and less distinct ones at 3.8 and 1.8kb. A human cmyc probe hybridised weakly to the 2.4kb species. The normal ARBO C9 cell line had mainly the 2.7kb species and A1SA5 the 2.4kb mRNA. There was no hybridisation with a human N-myc probe.
The neu oncogene has been implicated as the activating oncogene in some other ENU-induced glioblastomas (Bargmann et al. Cell, 45, 649, 1986) . There was no difference in the expression of a 5kb neu mRNA in the ARBO C9 and A15A5 cell lines suggesting that in this glioma any activation by neu is by small qualitative change in the gene rather than by alteration in the level of neu The c-mYc oncogene is involved in the regulation of cell proliferation; elevated levels of c-myc mRNA and its product p62c-myc have been detected in solid tumours and cell lines using molecular biological techniques. Oncogene expression has recently been assessed using monoclonal antibodies to oncoproteins generated against synthetic peptides. We studied c-myc expression in colorectal carcinomas from 100 patients, prospectively followed for 3 years, using Myc 1-6E10 which recognizes p62c-myc in paraffin-embedded material (Stewart et al., Br. J. Cancer, 53, 1, 1986) . Tissue sections were stained using an immunoperoxidase technique, and assessed independently by two observers. Paradoxically staining was predominantly cytoplasmic despite the reported nuclear location of p62c-myc (Evan & Hancock, Cell, 43, 253, 1985) . In normal mucosa, maturing crypt cells and surface epithelial cells were weakly positive. All carcinomas stained positively but with varying intensity. However, though distinctive staining patterns could be distinguished for both normal mucosa and for carcinomas, there was also considerable background staining of stromal elements. There was no significant relationship between staining intensity and conventional pathological features or prognosis. These results suggest that c-myc expression is a feature of normal maturing epithelial cells and that expression is increased in the majority of carcinomas and may be related to malignant transformation, but not to clinical behaviour. Paradoxical cytoplasmic and stromal staining may be due to fixation artefact. Alternatively in tissue sections Myc 1-6E10 may cross-react with proteins other than p62c-mjyc (cf. Evan et al., Mol. Cell. Biol., 5, 3610, 1985) . Data obtained on histological sections using this antibody should therefore be interpreted with caution. Recently we described the derivation of a series of human melanoma cell lines exhibiting differential lung colonising capacity in nude mice. (Ormerod et al., Cancer Res., 46, 884, 1986.) In the present study we have examined the response of these variants to activators of cyclic adenosine 3-5-monophosphate (cAMP).
The response of the low-metastatic parental DX3 line and the high-metastatic LT5. 1 variants to cholera toxin, forskolin, theopylline and melanocyte stimulating hormone was assessed in terms of in vitro growth rates, morphology, plating efficiencies and cAMP levels. Differences were found between the lines in the way that they responded to 10 -9 M cholera toxin such that the in vitro growth rate of the DX3 line was hardly affected by the presence of this agent whereas cell division of LT5. 1 variants ceased completely within 5-7 days although cAMP levels were elevated 5-10-fold in both lines. Pretreatment of LT5.1 cells prior to s.c. or i.v. injection into athymic nude mice retarded tumour growth and reduced lung nodules 3-5 fold respectively. Currently we are determining whether in vivo treatments can bring about similar reductions in metastatic burdens.
That variants of a human melanoma cell line show differential responses to cholera toxin might reflect differences in cAMP metabolism and its growth regulatory function in high and low metastatic lines. Cell division of the macrophage tumour M5076 is inhibited by a variety of agents known to induce differentiation in other tumours (Talmadge et al., Cancer Res., 42, 1850 , 1982 . The purpose of this study was to investigate the relationship between this response to one such agent, TPA, and the in vii'o behaviour of the cells.
A TPA resistant M5076 line (TPAR) was derived by culturing cells continually in 500ngml-I TPA. Exposure of the wild-type cells to 50ngml-1 TPA for 24h inhibited cellular proliferation by >95% as determined by [3H1-thymidine (3H-TdR) incorporation, whereas TPAR cells were still able to grow at I jig ml 1. The Fischer F344 rats were treated with a diet containing 0.06% 2-acetyl-aminofluorene (AAF), administered as a series of 2 week cycles separated by periods of carcinogen-free diet. During 4 such cycles they developed various liver lesions including cirrhosis, oval cell proliferation, foci of cells containing raised levels of gamma-glutamyl transpeptidase and hyperplastic nodules. Nine months after commencing AAF diet they began to develop primary hepatocellular carcinomas. Specimens of normal liver, tumour and preneoplastic liver were frozen for histological study, and both plasma membrane and total soluble extracts were prepared from these tissues. A panel of murine monoclonal antibodies to proteins coded by the nivc, mnb, r-as, sis, erb-B and src oncogenes were tested for reactivity with cryostat sections of normal liver, tumours and preneoplastic liver by immunoperoxidase staining. Reactivity with tissue extracts was tested by radio-immunoassay using 1 251-labelled anti- Recently discovered truncated MHC class I molecules have been implicated in the host response to cancer (Festenstein & Garrido, Nature, 332, 502, 1986) , and may be acting as serum blocking factors that suppress the immune response.
We have developed a method to measure class I and class I-like molecules in serum in order to investigate the possible relationship between the blood levels of these substances and tumour growth and metastasis. Class I material was partially purified from serum using lentil lectin coupled to Sepharose, this extract was labelled with I 125 and subjected to immunoprecipitation using various antibodies.
Two groups of antibody have been used; group A recognised classical K and D determinants, group B recognised molecules that were similar to class I MHC but were expressed on embryonal carcinomas. The immunoprecipitates were analysed using ID-SDS/PAGE electrophoresis followed by autoradiography. Using group A antibodies, molecules of 39-42 K daltons were identified in serum from healthy mice and animals bearing different types of tumour. The levels of these molecules were elevated in the tumour bearers and also appeared to be more marked if the tumours metastasised. Using group B antibodies, extra molecules at 34 and 36 K daltons were seen. The 36 K molecule appeared to be associated with liver metastasis, whereas the 34 K molecule was elevated in certain tumour-bearers. These results suggest that increased release of class I and class I-like molecules is occurring into the blood of tumour bearing mice; this process could have important consequences for the understanding and treatment of cancer.
Somatomedin-C (Sm-C)/insulin-like growth factor I is a mitogen for human small cell lung cancer (SCLC) demonstrated in a number of normal and neoplastic human tissues. In this study, tissues obtained from colonic carcinomas and non-neoplastic colonic mucosae were investigated for the presence of EGF receptors. Radio-ligand binding assays using 1-125 failed to show the presence of EGF receptors in three tumours and their corresponding normal mucosae. Immunoperoxidase studies, using EGF-Rl antibody, performed on 8 cases showed positive staining of both tumour and mucosa in 3 cases and positive staining of the mucosa only in 2 cases. These preliminary findings suggest that EGF receptors are present at a relatively low frequency in human colonic tissues. This contrasts with the findings of other workers who have shown EGFr to be absent from human colon. In rat colonic mucosa, EGF has been shown to act as a trophic agent in an organ culture system, thus implying the presence of EGFr.
Further experiments are being performed on larger numbers to investigate the presence of EGFr A range of drug-resistant sublines of the EMT6 mouse tumour cell line has been derived by continuous growth in increasing conCentrations of cytotoxic drugs. Sublines are now growing in adriamycin (ADM) (10 jug ml-') vincristine (VCR) (10yugml-'), colchicine (COL) (2ugml-1), Ro 31-1215 (1215) (0.1 igml -) and methotrexate (MTX) (10 ug ml -1). Cross-resistance patterns have been studied using a tetrazolium (MTT) colorimetric assay to measure growth inhibition during continuous drug exposure. Cells made resistant to ADM, VCR, COL or 1215 showed crossresistance to the other drugs in this group. The extent of resistance to 1215 (or to aclacinomycin A) was, however, considerably lower ( x 5-10) than it was to the other 3 agents ( x 20-100). These cells were all also highly resistant to VP16 ( x 20-50) and to mitozantrone ( x 50-300) but not to melphalan, CCNU or MTX. However, cells made resistant to MTX also showed a small degree of resistance to ADM, VCR and COL. These cells could be sensitised to ADM, but not to MTX, using the calcium transport blocker, verapamil. A monospecific antibody to the CP2 2 cytosolic calciumbinding protein (Koch et al, FEBS Letters, 195, 275, 1986) and immunoblotting have been used to quantify the presence of this protein in the various cells. Cellular content of CP22 increased progressively during the development of ADM resistance but dropped suddenly at the highest level of resistance. Increased levels of CP22 were seen in some but not all of the resistant lines and the amount did not predict for the extent of resistance to any given drug. Further studies using this antibody and also antibodies to the P-170 glycoprotein are in progress.
Evidence that multidrug resistance in Chinese hamster ovary cells is associated with alterations in the endoplasmic reticulum T47D human breast cancer cells were maintained in charcoal-stripped medium and exposed to oestradiol at various intervals prior to administration of etoposide (VP-16), a topoisomerase-I1-interactive drug. DNA strandbreakage measured by alkaline unwinding was 40% above control levels after 4 h of oestrogen exposure, and 85% above controls after 24h exposure. Oestrogen pre-treatment did not increase DNA damage induced by X-rays or bleomycin; however, administration of another topoisomerase-1I-interactive agent, mitoxantrone, led to a similar oestrogen-induced increase in damage to that witnessed with etoposide. No change in rate of DNA repair could be detected following either X-irradiation or etoposide treatment of cells pretreated with oestrogen when compared with controls. The degree of excess damage associated with oestrogen pre-treatment was reduced by either 4-hydroxytamoxifen or novobiocin co-administration, which is consistent with an increase in topoisomerase II levels accompanying oestrogen-induced cell activation. Moreover, the excess damage documented on alkaline unwinding could not be detected on nucleoid sedimentation, suggesting further that the differential strand-breakage is protein-(topoisomerase II)-associated. Dose-dependent inhibition of cell growth, clonogenicity and cell-cycle traverse varied directly with the extent of DNA damage induced in both oestrogentreated and control cells, and analysis of these data suggest the existence of a cellular subpopulation in which topoisomerase-1I-induced DNA damage may occur preferentially following cell activation by oestrogen. These findings raise the possibility that novel therapeutic strategies for established human breast cancer may be feasible using topoisomerase-I1-interactive drugs. The therapeutic effectiveness of drug-monoclonal antibody conjugates will depend partly on their biodistribution since if they are rapidly eliminated they are unlikely to reach the tumour target. In this study daunomycin-carrier-monoclonal antibody conjugates have been constructed with different chemical linkages and their biodistributions assessed.
Initially daunomycin (daun) was conjugated to human serum albumin (HSA) to molar substitution ratios of up to 20:1 either by reaction with 14-bromo-daunomycin to give a C-N bond between the 14-C of the drug and protein amino groups, or by reaction of succinylated HSA with the 14-bromo-daunomycin to give a succinyl ester linkage. Subsequently these dauno-HSA conjugates were linked to the 791T/36 monoclonal antibody via a thioether linkage at a 1:1 HSA:antibody molar ratio. For biodistribution studies the protein moieties of the dauno-HSA or dauno-HSA-791T/36 conjugates were labelled with radioiodine (1251 or 1311) and blood survival and biodistribution in mice compared with radio-iodine labelled HSA, succinylated HSA HSA-791T/36 and 791T/36 alone. With the 14-C linked conjugates, blood survival of dauno-HSA, and dauno-HSA-791T/36 were similar to those of HSA or antibody. Blood contained more radiolabel than any other organ, the survivals at 24h being 27% for 791T/36 antibody, 19.1% for HSA and 20.4% for dauno-HSA-791T/36. In contrast, with the succinyl ester linkage, dauno-HSA and dauno-HSA-791T/36 were rapidly cleared from the blood, particularly to liver and spleen so that blood survivals were <I % at 24 h. There is a certain lack of unanimity on the prognostic significance of DNA ploidy in colorectal carcinoma, which is apparent from the different aneuploidy rates (14-67%) in various published studies (Perrez et al, Br. J. Cancer, 43, 526, 1981; Rognum et al ibid, 45, 921, 1982; Woolley et al, J. Natl Cancer Inst., 69, 15, 1982) , and from the interpretation of the biological significance of the phenomenon. 119 consecutive patients presenting from 1981-83 were prospectively studied. DNA ploidy status was determined by flow cytometry according to the method of Hedley et al., (J. Histochem. Cytochem., 31, 1333, 1983 In a study of 15 patients given 2.5mg of 131I polyclonal sheep or goat antibody against carcino-embryonic antigen for therapy of advanced colorectal cancer 9/15 (60%) developed human anti-antibodies measured by ELISA. For effective tumour therapy anti-tumour antibodies need to be given on several occasions. The presence of anti-antibodies increases the clearance of the anti-tumour antibody and can lead to severe hypersensitivity reactions if therapy is repeated. We examined methods of inhibiting the immune response to xenogeneic antibodies in rabbits, using the immunosuppressive agent cyclosporin (CyA). The immunogen was 200 ,g of the mouse monoclonal antihuman chorionic gonadotrophin antibody, injected i.v. The antibody was prepared from ascites and immunopurified. Some animals were given antibody which had been 'deaggregated' by ultracentrifugation. The CyA, 20mg kg-I i.m. was given for 6 days starting day -1 and this regimen was repeated when the animals were re-challenged at 14 days. In those animals given CyA the clearance of the antibody was significantly prolonged and the rabbit antimouse antibody response measured by ELISA was suppressed in 8/8 animals given 'deaggregated' antibody and 6/8 given the standard preparation. 'Deaggregated' antibody alone did not inhibit the immune response.
These experiments indicate that CyA may be a suitable agent to inhibit the anti-antibody response in humans to xenogeneic antibodies used for tumour therapy. The NMU and DMBA rat mammary tumour models are well established as in vivo systems for testing antitumour activity of drugs. We therefore used the NMU-induced primary tumour model to study the effects of rHuTNF and rIFN-y on mammary tumour growth.
An inbred strain of female Ludwig/Wistar/Olac rats with NMU-induced mammary tumours were randomized to either treatment or control groups, each containing 12-18 animals. Treatment groups received either 50,pg rHuTNF and 30,000 units rIFN-y as a combined dose or 100 pg TNF alone: control groups received saline. Tumour growth was monitored twice weekly for 4 weeks.
Tumour size in control groups increased almost linearly over this period. Treatment with a combined dose of rIFN-y and rHuTNF reduced tumour growth with 44% regression after 4 weeks. If rHuTNF was administered alone initial tumour regression was noted in the first week (-25%) after which the tumours appeared to regrow at rates similar to that of control animals, ylFN alone had no effect. Evidence from in vitro cell culture studies suggests that rIFN-y can upregulate TNF receptors.
In conclusion we have demonstrated that the combination The glutathione S-transferase (GS-T) enzymes are known to be involved in the deactivation of a wide variety of electrophilic species within the cell. The activity of these enzymes has been measured in cell extracts from parental Yoshida sarcoma cells (YS) together with cell lines which have been made resistant to the alkylating agents cyclophosphamide (YR cyclo), busulphan (YR bus), and methylene dimethane sulphonate (YR 8) , by incremental challenge with the relevant drug in vitro. Glutathione S-transferase activities were determined spectrophotometrically using 1-chloro-2, 4-dinitrobenzene (CDNB) and glutathione as cosubstrates. The resistant cell lines all show elevated GS-T activities compared with the parental cell line. The levels of elevation are 4-fold for the YR bus and YR 8 cell lines, and 6-fold for the YR cyclo cell line. All three alkylating agents can inhibit GS-T activity against CDNB. It is proposed that a part of the resistance mechanism operating in these cell lines is due to an increased deactivation of alkylating species by the elevated levels of GS-T enzymes. This may also account for the cross resistance observed between these cell lines and alkylating agents, as well as the decreased damage to cellular DNA, as measured by alkaline elution and inhibition of DNA synthesis, observed in the resistant cell lines. 83, 2496, 1986) . This finding has important implications for studies designed to elucidate the mechanisms of action of oestrogens and anti-oestrogens using human breast cancer cell lines in long-term culture.
In culture medium containing PR and 5% dextran coated charcoal stripped foetal calf serum (FCSdcc), cell population doubling time, (DT), of ZR-75-1 human breast cancer cells was 2-2.9 days for cells initially plated at 1-5 x 104 per microwell plate. Cells expressed both ER, (147 + 19 fmol mg-1 protein) and PGR, (80 + 24 fmol mg-I protein) as assessed using a whole cell binding assay. Cells transferred to PR free medium containing 5% FCSdcc showed an immediate slowing of growth rate at an initial seeding density of 5 x 104 cells per well, (DT 4.1-5 days). Continuous exposure to oestradiol, (10-9 M), shortened DT to 3 days. This effect was most consistent when the serum concentration was raised to 20%. PR deprived cells retained sensitivity to oestrogen reversible growth inhibition by 4-hydroxy tamoxifen (10-9_ 10-7 M). Cells plated at densities <4 x 104/well failed to proliferate in the absence of phenol red.
The DT of cells deprived of PR for 4 months has extended to 8.4-10 days and remains at 5.6-6 days in the presence of oestradiol. ER Whilst the majority of breast tumours which respond to endocrine manipulation contain oestrogen receptors (ER) some tumours which do not have ER respond to these therapies. We have examined the ability of pharmacological and suprapharmacological concentrations of both E2 and TAM to modulate the membrane fluidity of MCF-7 (E2 responsive) and MDA-MB-436 (E2 unresponsive) cells as determined by the steady-state polarisation of fluorescence of the probe 1,6 diphenylhexatriene. The ability of E2 and TAM to influence cell proliferation was also determined. E2 produces an equivalent increase in membrane fluidity in both cell lines, oestrogenic effects being observed only in MCF-7 cells. In both MCF-7 and MDA-MB-436 cells 1O-M E2 is equitoxic and produces similar perturbations in membrane fluidity. 10 6 M TAM decreases the membrane fluidity in both cell lines but inhibition of proliferation reversible by E2 is observed only in MCF-7 cells. 10-M TAM is less cytotoxic towards MDA-MB-436 cells than MCF-7 cells and produces less perturbation of membrane fluidity.
The inhibitory effects of high doses of E2 and TAM are unlikely to be mediated through the ER and may be the result of altered membrane function. We have previously demonstrated that 10 -6M E2 reduces the steady-state levels of methotrexate in both MCF-7 (Clarke et al, Br. J. Cancer, 51, 365, 1985) and MDA-MB-436 cells (Clarke et al, Eur. J. Cancer Clin. Oncol., 17, 1275 Oncol., 17, , 1983 (11) In both series the R7A/L1210 ratio decreased as the N10-chain length increased (paralleling the decrease in the Ki TS/Ki DHFR ratio). The greater degree of cross-resistance towards the desamino series is not readily explained. The application of ricin or ricin A-chain conjugates as selective cytotoxins in vivo has proven to be a difficult objective to achieve both because of the affinity of the whole toxins for non-target cells and because of other pharmacokinetic considerations. The substitution of less interactive molecular species in place of ricin may go some way towards resolving these problems and we present here a study on the selective delivery of the radio-sensitising compound 5-bromo-2'-deoxyuridine to the human adenocarcinoma cell line HT29/5. The route of intra-cellular delivery chosen was by conjugation to transferrin (thereby utilising the transferrin receptor internalisation pathway) or to the AUA1 monoclonal antibody. To increase the loading of the carrier with bromodeoxyuridine without impairing its ability to bind to its cellular target the radiosensitiser was first linked to poly-L-lysine which was in turn conjugated via succinimidyl 4-(p-maleimidophenol) to Rhodamine 6G (R6G), a mitochondrial dye, has been shown to act via inhibition of oxidative phosphorylation. Incubation of a human non-small cell lung cancer cell line, WIL, in the presence of R6G (1-10 iM) resulted in a decrease in the rate of oxygen consumption by the cells by up to 50%. In contrast, the rate of anaerobic metabolism, estimated as the rate of lactate production by the cells, was increased by up to 60% in the presence of R6G (1-1O0M). The magnitude of both these changes was dose dependent.
However, even at a concentration of 1O M, R6G had no significant effect on either oxygen uptake or lactate production by freshly prepared rat liver hepatocytes.
The doubling time of the Wl L tumour, grown as a xenograft in athymic mice, was increased by about 30% after a single i.p. injection of R6G (2mg kg-1). A single i.p. injection of 5-fluorouracil (50mg kg-1), a known inhibitor of mitochondrial biogenesis, had no effect on tumour doubling time. However, combination of R6G (2 mg kg -1) and 5-fluorouracil (50mgkg-1) resulted in an increase in tumour doubling time of greater than 100%.
These results demonstrate a selective inhibition of aerobic metabolism in tumour cells by R6G which may be compensated for, in part, by an increase in the rate of anaerobic metabolism. Inhibition of tumour growth in vivo by R6G is enhanced by a non-cytotoxic dose of 5-fluorouracil. This may be the result of an inhibition of tumour cell mitochondrial biogenesis. Conditioned medium from feeder cells is variable in its ability to enhance clonogenicity of the same cells, and little is known concerning the mechanisms underlying the epithelial -mesenchymal interactions. A model using mesothelial cells (MC) and an ovarian tumour cell line (TC) has been used to investigate possible mechanisms, and results suggest that polyamines may be implicated. In the model used MC can respond to mitogenic stimulation and clonogenicity of MC can therefore be determined in parallel with TC. Results suggest that the responsiveness of MC to EGF influences interactions between MC, TC, EGF and an amine oxidase inhibitor-iproniazid, (IP). Late passage MC with reduced responsiveness to EGF fail to enhance to growth in the presence of EGF. Stimulation can be restored in the presence of IP which does not itself affect either TC or MC clonogenicity. Conversely early passage MC, which are very responsive to EGF still stimulate to clonogenicity in the presence and absence of EGF. In these circumstances, IP has no effect on enhancement of TC clonogenicity by MC. Experiments are in progress to evaluate the role of polyamine metabolism in more detail. The mode of action of cytotoxic melamines is unknown. Although the requirement for N-hydroxymethyl groups is well established, whether formed by metabolic activation (HMM, PMM) or chemical synthesis (Trimelamol), there is still little evidence to indicate that DNA alkylation is the cause of cytotoxicity. Trimelamol (T) at 100lIM for 4h did not affect calf thymus DNA template activity. Exposure to T at lOO1UM for 2h caused 46% inhibition of 3H-TdR incorporation by PC6 cells in vitro but this was completely abolished by semicarbazide (SC) pretreatment (i.e., formaldehyde (F) trapping). However, SC had little effect on the inhibition of growth of PC6 cells in vitro by T 125-400pM, merely reducing mean inhibition from 62% to 55%. Hence F release contributes little to toxicity in this cell line. Treatment of Balb C-mice bearing PC6 ascites tumour with T 50mg kg-1 i.v. daily x 3 gave a 77% prolongation in survival. In addition to showing in vivo sensitivity, the PC6 tumour proved to be predictive for anti-tumour activity of T in man both in terms of an effective plasma concentration and schedule dependent differences in therapeutic index. Hence the PC6 is a suitable model for mechanistic investigations. A 29% inhibitory effect on 3H-TdR incorporation by PC6 ascites cells removed 2 h after T 100mg kg-1 i.v., was virtually absent (5%) by 5 h. Flow cytometric analysis of T-treated PC6 cells failed to show a G2 block suggesting that DNA-DNA x-linking is not an important event. Nevertheless T did cause imbalanced growth in PC6 cells at 50-100UM in vitro as shown by an increase in cell size (70%) and protein content (67%) at 24h. This was associated with a small reduction in G1 and an increase in S phase cells. Thus T appears to affect the regulation of cell division in this sensitive cell line but the mechanism of this activity remains obscure. NMF is one of a number of polar solvents which can induce the terminal differentiation of certain malignant cell lines in vitro. We have previously demonstrated an NMF concentration-dependent decrease in the growth rate and an associated G1 phase accumulation of murine TLX5 lymphoma cells in vitro (Bill et al, Br. J. Cancer, 54, 168, 1986) . In this study we investigated further the G1 phase sub-compartments of TLX5 cells incubated with NMF in vitro and assessed whether or not terminal differentiation had resulted from the drug exposure. Simultaneous DNA and RNA analysis of TLX5 cells treated with NMF in vitro by flow cytometry revealed a concentration-dependent decrease in cellular RNA content, indicative of an early G1 phase arrest. TLX5 cells exposed to 170mm NMF for 48h resulted in 99.7% of the G1 population in the subcompartment with the lowest RNA content, termed G1A9 whereas for TLX5 cells at plateau phase for 3 days GI A contained 88.5% of G, phase cells. TLX5 cells were incubated with 106 mm NMF for 48 h, cells were then washed free of the drug and cultured in fresh medium. There was an initial fall in viability (82 + 3% to 45 + 4%) as measured by trypan blue exclusion and rise in the viable G, phase population (77% to 95%) 24h after NMF removal. However, by 72 h a normal control cell cycle distribution was evident. Anchorage independent growth analysis of these cells in soft agar, plated immediately after NMF was removed from the medium gave a clonogenic efficiency of 54.5 +4.3% of the control value, indicating complete proliferative recovery of the viable cell population. We conclude that murine TLX5 lymphoma cells exposed to NMF in vitro are not terminally differentiated, but reside in a quiescent substate which was reversed on drug removal. Results of clinical trials of N-methylformamide (OHCNHCH3, NMF) indicate that its therapeutic potential is low. The major toxicities of NMF in patients were nonspecific malaise and liver damage. During investigations on the formyl-deuterated isotopomer of NMF (ODCNHCH3, D-NMF) a primary kinetic isotope effect on the metabolism of NMF to methylamine and N-aeetyl-S-(Nmethylcarbamoyl)cysteine (Threadgill et al, Br. J. Cancer, 54, 193, 1986) was discovered. In order to establish whether this metabolic pathway is involved in the mechanism of the antitumour activity of NMF, the efficacy of D-NMF was tested against the M5076 reticulum cell sarcoma grown in female BDF1 mice. The compound was administered i.p. daily for 17 consecutive days and tumour volumes were measured at regular intervals. D-NMF at 100mgkg-I was inactive and at 200mgkg-I it afforded a T/C value of 28 (mean of 5 mice), which is almost identical to the activity observed with 100mgkg-' NMF. At a dose of D-NMF of 400 mg kg-1, tumour volume was not measurable. The difference between D-NMF and NMF in toxicity was most dramatic. At 800mg kg -D-NMF did not cause weight loss, whereas 300mg kg-1 of NMF was near the LD50 in BDF1 mice. Two conclusions can be drawn from these results: (i) Cleavage of the formyl C-H bond appears to be a prelude to the generation of both the antitumour activity and toxicities of NMF. (ii) The startling reduction of toxicity on substitution of the formyl H with D indicates that the doselimiting toxicity of NMF in mice is possibly mediated by processes other than or additional to the hepatic lesion. A number of in vitro systems have been used to examine the potential of a variety of agents to induce the terminal differentiation of malignant cells. Few attempts have been made to conduct such experiments under conditions of appropriate drug pharmacodynamics in vitro, and fewer have utilised an in vivo assay of drug-induced terminal differentiation. We have investigated the growth characteristics of the human promyelocytic leukaemia HL-60 cells when they were implanted in millipore chambers, into 20g, female CBA/CA mice. Growth characteristics in chambers were dependent on a number of variables. When 150 p1 of 1 x 106 HL-60 cellsml-' in RPMI 1640 medium (+10% foetal calf serum), which had an in vitro doubling time of 24 h, were implanted in chambers, with a pore size of 0.45 pm, immediate and rapid growth (doubling time =8 h) was observed when the chambers were adjacent to the incision wound (final cell density= 1.3 x 107 cells ml I on day 2). When distal from the wound site a growth lag of 72 h was observed, followed by log. phase growth (doubling time =24 h) to plateau at 168 h at 2 x 107cells ml-'. Under these conditions, growth characteristics were optimally reproducible when an initial cell density of 1 x 106 cells ml-1 and a 0.45 pm Millipore filter was used. In the absence of serum in the chamber, spontaneous differentiation, assessed by biochemical and morphological tests, was < 10% in cells which had been implanted 22 days earlier. We consider this to be a potentially useful model for assessing drug-induced terminal cell differentiation in vivo. I -(2 -chloroethyl) 3 -[ 2 -(dimethylaminosulphonyl) ethyl I -1 -nitrosourea (TCNU) is a new nitrosourea with greater water solubility. Following improved activity over other nitrosoureas in experimental tumour systems it has undergone Phase I evaluation. Objective responses have been seen in squamous cell, adenocarcinoma and large cell carcinoma of the lung as well as in mesothelioma and breast cancer. Phase 11 evaluation in non-small cell lung cancer, melanoma, breast cancer and colorectal carcinoma are now in progress. The purpose of this study was to examine its activity in a panel of transplantable adenocarcinomas of the mouse colon with varying sensitivities to standard nitrosoureas. Chemosensitivity was assessed in three tumour lines, the ascitic line MAC 15A, a poorly differentiated subcutaneous solid tumour MAC 13 and a well differentiated solid tumour MAC 26. Effects of treatment were determined as previously described (Double et al, Br. J. Cancer, 54, 595, 1986 125, 1985) . These findings suggest that more effective platinum derivatives may be discovered with suitably predictive screening models. The limitations and disparate predictiveness of widely used experimental tumours (L1210 and ADJ/PC6 plasmacytoma) and their cis-platinresistant variants are presented in the light of the established clinical requirements. Preliminary studies with a number of human ovarian tumour xenografts grown in the nude mouse suggest that a panel of such tumours, characterised for sensitivity against appropriate reference platinum drugs (cisplatin, carboplatin, iproplatin, tetraplatin), may be of greater utility in the development of novel platinum agents. Preliminary studies in this laboratory with I-(2-chloroethyl) 3-[2-(dimethylaminosulphonyl)ethyl]-I -nitrosourea (TCNU) have been shown to be highly active against transplantable mouse colon tumours (MAC). In vivo pharmacokinetics and in vitro stability of TCNU have been studied using a reverse phase HPLC technique giving a sensitivity of 5 ng ml-1 Rate of breakdown of TCNU at 37°C in vitro in the dark was 0.14gmin-I in mouse plasma, 0.08gmin-I in human plasma, 0.10gmin-1 in PBS and 0.llgmin-1 in RPMI 1640 with 10% foetal calf serum. Rate of breakdown in 0.9% saline at 20C on the bench was 0.02gmin-1. Non tumour bearing NMRI mice were injected i.p. with therapeutic doses of TCNU in 0.9% saline and plasma profiles measured between 0-4 h. TCNU was not detectable in the plasma at 2 h. In vitro cell lines were derived from 3 transplantable MAC tumours of differing growth charac-teristics and histology MAC 13, MAC 15A and MAC 26. Chemosensitivity to TCNU was determined at a range of concentration and exposure times for each of these lines using a modified clonogenic assay (Hamburger & Salmon, Science, 187, 461, 1977) Two sublines have been derived from a human bladder carcinoma cell line (RT 112-P) by either continuous exposure to cis-platin (RT112-CP+) or to fractionated X-irradiation (RTI 12-DXR8). In vitro sensitivities to cis-platin were determined by clonogenic assay following a 1 h exposure to drug. The RTI 12-DXR8 subline exhibited a 1.6-fold hypersensitivity and the RTl 12-CP + subline a 2-fold resistance to cis-platin compared to the parent cells (IC50 for RTI 12-P is .1 yg ml-1). Similar patterns of cross-resistance and collateral sensitivity to carboplatin and iproplatin were also observed. Since DNA is considered an important target for the cytotoxic action of cis-platin, DNA-DNA interstrand crosslinking and single-strand breakage were quantitated in these lines at 0, 5, 14 and 24h, following a 1 h in vitro exposure to drug, by the technique of alkaline elution. Interstrand crosslinks were induced to a far greater extent in the sensitive subline and to a similar extent in the resistant subline, when compared to the parent, with peak levels of 126.5, 52.8 and 58.2 rad-equivalents respectively. A significantly increased uptake of 195mcis-platin was noted in the sensitive subline with a similar uptake in the resistant line compared to the parent cells, whereas the extent of binding to DNA was comparable in all three lines. Significantly increased levels of both glutathione and glutathione reductase occurred in the RTl 12-CP + cells compared to the parent and RTl 1 2-DXR8 cells, which had similar levels. Therefore, the underlying mechanisms of resistance or collateeal sensitivity to cis-platin may not be conversely related. One of the main problems concerned with the production of human monoclonal antibodies has been the limited availability of a suitable fusion partner. Past problems include low Ig production, low fusion success rate, and instability of hybrids. We are concerned with the production of alternative fusion partners and comparing them with other lines used in Human X Human B lymphocyte fusions. Using lymphocytes taken from a patient with plasma cell leukaemia (PCL) at plasmaphoresis, we attempted to obtain better immortal lines by growing the cells in nude mice, which up to the present has been unsuccessful, but by hybridisation with UC729-6 four cell lines have been produced. The hybrid nature of the cells have been confirmed by examination of the ploidy on a FACS 420. Tissue typing for histocompatibility antigens showed in addition to the presence of antigens associated with the UC729-6, those of the plasma cell leukaemia. Surface and cytoplasmic immunoglobulin characteristics have been examined using the FACS and enzyme linked immunoabsorbent assay. All cell lines produced IgA, lambda of the PCL parent and varying levels of IgM, known to be produced by The difference in sensitivity to cis-platinum (cis-DDP) between 2 human ovarian adenocarcinoma cell lines established from ascites samples from one patient before (PEOI) and after (PE04) the onset of clinical resistance to the drug was studied using the technique of alkaline elution.
After 5 h of treatment with 50 pM cis-DDP no significant difference in total cross-linking as expressed in rad equivalents was observed between the two cell lines. There was however a 2-3 fold difference in protease-resistant cross-linking between PEOI and PE04; see We have studied the response of bone marrow cells to cytotoxic drugs as a model for evaluating the regulation of glutathione-dependent enzymes as stress response proteins. The model chosen is based on the observation that when mice are dosed with a low 'priming' dose of cyclophosamide, they become resistant to a subsequent potentially lethal dose given 5 to 6 days later (Millar et al, Br. J. Cancer, 32, 193, 1975 Glutathione and glutathione-dependent enzymes such as the glutathione-S-transferases (Gsts) play a central role in the protection of cells from cytotoxic and carcinogenic compounds. However, relatively little is known about the glutathione levels and Gst expression in tumour cells. Nevertheless, there is evidence which indicates that it is an important factor in tumour cell susceptibility to anticancer drugs. As a consequence the expression of Gst in 10 tumour cell lines of different origin has been studied. A large variation in Gst activity, determined using CDNB as a substrate was measured. The human breast cancer cell line MCF-7 had extremely low activity and was 100 fold less than either the ovarian cell line PE-04 or the non-small cell lung carcinoma line H358. Western blots of soluble fractions from these lines using antibodies raised against human Gsts basic (e, YaYa), neutral (,u, YbYb) and acidic (x., YfYf) showed high levels of the acidic YfYf poltpeptide (an enzyme which has been associated with drug resistance) in most of the cell lines studied. Ovarian adenocarcinoma cell line PE-04, lung carcinoma line H358 and the human bladder carcinoma line EJ contained highest levels of this Science, 197, 165, 1977 (Leopold et al., Cancer Res., 45, 5532, 1985) and is currently undergoing phase I clinical evaluation. We have examined the effect of C1941 on adriamycin free radical generation, superoxide formation and lipid peroxidation, using rat liver microsomes fortified with NADPH. The results show that C1941 can inhibit adriamycin (50 iM) induced NADPH consumption (56% inhibition at 50 jiM C1941). Electron spin resonance studies have shown that C1941 can diminish the adriamycin drug free radical signal in a dose dependent manner. Similarly adriamycin superoxide formation (using purified cyt. P450 reductase) can be inhibited by C1941 (IC50 = 75pM). An examination of the effects of the two agents on lipid peroxidation reveals that C1941 is a potent inhibitor of adriamycin stimulated lipid peroxidation (IC50 = 5 gM). In conclusion therefore, the inhibitory effect of C1941 on adriamycin activation may form the basis for the combined use of the two drugs in attempts to diminish adriamycin cardiotoxicity. The interaction of doxorubicin and mitozantrone with myoglobin has been investigated to establish whether this haemoprotein could be involved in the cardiotoxic actions of these antitumour agents. Oxymyoglobin (MbFe(II)02) and metmyoglobin (MbFe(III)) were prepared as described by Taylor & Hochstein, (Biochem. Pharmacol., 27, 2079 , 1978 The antioxidant ethoxyquin (EQ) has been shown both to inhibit tumour formation, mainly in liver, and also to act as a tumour promoter in some extrahepatic tissues. At a dose (0.5% in the diet) which completely inhibited induction of hepatocellular preneoplastic foci by aflatoxin B1, considerable renal damage was observed in 30 week old Fischer rats after 23 weeks of EQ treatment. Many of the pathological changes resembled those of chronic progressive glomerulonephrosis (CPGN), normally seen in very old animals, suggesting that EQ was accelerating the ageing process. Formation of haemosiderin and large amounts of lipofuscin were prominent in tubular cells. In addition to the changes of CPGN, EQ treated kidneys contained many hyperplastic tubules and small nodules of epithelial proliferation, often obliterating the lumen. Such changes are potentially preneoplastic and may be the precursors of adenocarcinomas. These hyperplastic tubules differed in a number of respects from those occasionally seen in CPGN and support for their preneoplastic nature was obtained by their basophilic staining with H and E, loss of GGT activity and PAS-positive brush borders, and strong staining for guanidinobenzoatase; hyperplastic tubules of CPGN do not stain for this tumour-associated enzyme. EQ-treated kidneys also showed induction for one or more isozymes of gamma glutamyl transpeptidase and glutathione S-transferase P (7-7 form), mainly in undamaged tubules of the outer cortex. Results suggested that EQ might be exerting a carcinogenic action in the kidney. 06-ethylguanine (06-etG) , or one 04-methylthymine (04-meT) residue have been synthesized by the phosphotriester approach in solution. They anneal to give double-stranded DNA in solution. The structure of double helices containing 06-meG: cytosine (C), 06-meG: thymine (T), 06-etG: C, and G: 04-meT base-pairs have been studied by NMR. The helices were right-handed with every nucleoside having the anti glycosidic torsion angle found in B-DNA. The modified bases stacked into the helix, and the alkyl groups were shown to be in the major groove of the DNA. NMR and optical melting profiles indicate that the helices are less stable than the non-alkylated parents but only in helices containing 06-etG did the 3 spectrum give evidence of severe distortion of the phosphodiester backbone of the DNA. It has previously been believed that 06-meG forms a stable base-pair with T and that 04-meT forms one with G, and that in these base-pairs the imino protons of T and G are hydrogen bonded to N(l) or N(3) of the alkylated base. However, NMR shows that these protons are not involved in strong hydrogen bonds and casts doubt on the accepted structures for 04-meT:G and 06-alkylG:T mispairs. Radiat. Oncol. Biol. Phys., 12, 1087 , 1986 . This contrasts with low tumour to plasma ratios obtained in a previous study of RSU 1069 in the KHT sarcoma (Workman & Walton, Int. J. Radiat. Oncol. Biol. Phys., 10, 1307, 1984) . We describe here experiments designed to determine the basis for the very large difference between these tumour systems for their uptake of RSU 1069.
The pharmacokinetics of RSU 1069 has been studied in C57 mice carrying the B16 or Lewis Lung tumours and in C3H mice bearing the KHT tumour. In each strain of mouse the maximum brain to plasma ratio was always less than 1.0, whereas the tumour/plasma ratio was 3.8, 0.5 and 0.4 for the B16, KHT and Lewis Lung tumours respectively. In order to test whether the differences observed have a cellular basis, drug uptake experiments were carried out in vitro using freshly exised tumour cells from B 16, KHT, Lewis Lung, HX34 and HX118 tumours, the latter two are human amelanotic and melanotic melanoma xenografts respectively. Uptake of RSU 1069 into B16 melanoma cells in vitro is pH dependent. Values of the ratio of internal to external concentration (Ci/Ce) were 0.99, 1.35, 1.88 and 3.04 when cells were exposed at pH 5. 4, 6.4, 7.4 A large number of ascitic/peritoneal fluids have been tests for colony-stimulating-activity against tumour cells (TC) and transforming activity against mesothelial cells (MC) in a soft agar assay. A proportion of these fluids were found to induce varying degrees of spreading of MC in soft agar, leading to monolayer formation in some cases. Limited spreading of tumour cells also occurred. Addition of some of these fluids to monolayers of TC or MC resulted in visible formation of a fibrin mat which bound to the surface of MC but not to 4/4 ovarian tumour cell lines. Only one of these fluids had measurable levels of fibrinogen, though all had high levels of FDP. It was noteworthy that the majority of fluids which caused high-grade spreading came from patients who had not been exposed to chemotherapy. Fibrin mats in association with cells could be identified under phase contrast in the soft agar, and spreading of cells was presumably due to interaction between fibrin and the cell. It is suggested that the soft agar model provides a novel system for studying interactions between fibrin and normal cells or TC. The system also allows study of Anti-sense oligodeoxynucleotides (20-mers) complementary to the untranslated sequence and codon 12 region of the human EJ/T24 Ha-ras gene have been synthesized and are being tested for effects on gene expression in ras-transformed NIH 3T3 cells. A system for post-synthesis end-on coupling of deprotected oligonucleotides to cell delivery molecules such as antibodies or polypeptides has been perfected. This comprises the coupling of the new agent 9-fluorenylmethoxycarbonyl -6 -amino -I -hexanol-I -0-(2-chlorophenyl-Ibenzotriazolyl)phosphate as the last step of phosphotriester synthesis. Following normal deprotection procedures a strongly nucleophilic free amino group is generated which participates readily in protein cross-linking reactions. The simplicity of the entire procedure was demonstrated by the synthesis of oligo(dT)20-5'-0-(6-amino-I -hexanol) phosphate and its subsequent crosslinking to poly-L-lysine with dithiobis (succinimidyl propionate). We have also investigated the synthesis of oligonucleotide analogues containing modifications to the normal phosphodiester linkage. The novel analogue monomer, 5'-0-dimethoxytritylthymidine-3'-0-(4-anisidino)phosphate was synthesized and incorporated into oligonucleotides, however, the coupling efficiency was only 50% and therefore it could only be used realistically as a means of protecting 3'-termini from exonucleolytic degradation. Higher coupling efficiencies were achieved with fully protected 2'-deoxy-ribonucleoside-3'-0-(1-benzo-triazolyl)methylphosphonates (50-80%) and oncogene anti-sense oligonucleotides incorporating these entities are being synthesized in an attempt to influence gene expression from without. A number of proto-and viral oncogene products, which are considered to be involved in malignant transformation, are tyrosine specific protein kinases. Quercetin, 3, 3', 4', 5, hydroxyflavone, a naturally occurring plant product, has been shown to inhibit the transforming gene product of the Rous Sarcoma virus, pp6Osrc (Glossman et al., Naunyn Schmeidebergs Arch. Pharmacol., 317, 100, 1981) . pp6osrc is responsible for the transformation of certain cell types and its activity is required for the maintenance of the transformed phenotype. Since the inhibition of pp6Osrc by quercetin is only one of its many activities, it is the aim of this project to synthesise rationally a series of analogues of quercetin that may show specific activity against pp6osrc and other associated tyrosine protein kinases. Compounds were synthesized by the acylation of 4,6-disubstituted 2-hydroxyacetophenones with 3,4-disubstituted benzoyl chlorides, followed by base catalyzed rearrangement and acid catalyzed ring closure. The results of cytotoxicity assays using Abelson-transformed NIH3T3 cells (ANN-1 cells) which express the Abelson tyrosine-protein kinase, show a range of I.C.5os from 8 pM (3'4'-dihydroxyflavone) to 91 yM (quercetin). Cytogenetic analysis of 6 long-term colon adenocarcinoma cell lines has been undertaken, and the results compared with those obtained from freshly derived short-term cultured (6 h) tumour cells. With established cell lines the cytogenetic characteristics included deletions, translocation events, addition and absence of chromosomes as well as the identification of a number of marker chromosomes, and other chromosomal abnormalities. A consistent feature of the cell lines was the prominent involvement of chromosomes numbers 5, 7, It, 19 and 20 , and the absence of the Y chromosome in tumours of male origin. In many of the commonly used SW cell lines up to five genotypically distinct subpopulations could be identified inferring considerable heterogeneity within any given cell line.
Analysis of freshly derived colon adenocarcinoma cells also showed genotypic heterogeneity within a given population, and the predominant population exhibited many of the characteristics associated with established cell lines:
vi,-. additional chromosomes 5, 7, 11 and 20 and abnormalities in chromosomes 2, 3 and 19. It will be of considerable importance in further studies to define the phenotypic and biological characteristics associated with apparent genotypic changes. The cells within a tumour are known to be heterogeneous with regard to their metastatic capability. Environmental agents and drug treatments can both induce stable alterations in gene expression which are then reflected in heritable behavioural changes. To study the possible effect of such drugs on metastasis, the tumorigenicity and metastatic behaviour of a murine mammary tumour (P574) were studied before and after treatment in vitro with two drugs, 5-aza-2'-deoxycytidine (a hypomethylating agent), and tetradecanoylphorbolacetate (TPA), a known promotor of murine skin tumours. P574 cells were treated in vitro with a single dose of either drug (5 ,um 5-aza-2'-deoxycytidine, 10 ng ml-1 TPA) for times varying from 1-24 h. After 24 h recovery, cells were inoculated into the fat pad of syngeneic mice and the effects on tumour growth and metastatic behaviour were documented.
P574 normally has a latent period of tumourigenicity of 12 weeks and is only weakly spontaneously metastatic. Both drugs accelerated the growth of fat pad tumours and significantly increased the numbers of pulmonary metastases. This increase in spontaneous tumour spread must reflect a heritable change induced by the drug treatments as many generations of cell division occur between tumour cell inoculation and metastases. The effect of basement membrane components (laminin, fibronectin and type IV collagen) on type IV collagenase and plasminogen activator secretion was investigated in a primary HSV-2 induced hamster fibrosarcoma, and its in vivo derived sublines and in vitro derived clones of previously defined high or low metastatic potential. Fibronectin and type IV collagen were ineffective in influencing the expression of either type IV collagenase or plasminogen activator activity. Laminin however, at concentrations of 1-lOpgml-1, when added to serum-free cultured supernatants, increased the release of type IV collagenase by up to 100% for the parental cell line. Three highly metastatic sublines (two in vivo derived, and one in vitro cloned) showed increases of up to 300% in type IV collagenase secretion upon laminin stimulation; in contrast non-metastatic sublines (two in vivo and one in vitro cloned) showed no increase in type IV collagenase activity in response to laminin. Plasminogen activator released from either the parental cell line or its metastatic sublines and clones was unaffected by the addition of laminin. These studies infer a role for laminin, via its interaction with the laminin receptor site on tumour cells, leading to an increase in type IV collagenase secretion; this process may contribute to the process of tumour metastases and invasion of tumour cells through basement membrane matrices.
Introduction of an activated c-Ha-ras-1 gene by transfection with the pSV2-neo vector has been shown to enhance the spontaneous metastatic capacity of syngeneic mouse mammary carcinoma cells from <10% incidence to >90%. (Vousden et al., Int. J. Cancer, 37, 425, 1986) . Control transfectants (pSV2-neo alone) showed a slightly increased tendency to metastasize which was rapidly lost during in vitro or in vivo passage, whereas the ras-induced metastatic phenotype appeared stable. Various parameters are being investigated with the aim of elucidating the mechanism of action of this oncogene. Ras mutants with a serine residue at codon 12 were capable of inducing metastasis of transfected cells, indicating that the glycine-+valine mutation is not unique in this capacity. The ras transfectants were found not to differ significantly from the parental or pSV2-neo controls in terms of: growth rate, immunogenicity, ploidy, collagenase activity, size distribution of cell surface glycopeptides, or lung colonisation potential. We infer from these data that the ras oncogene influences as yet unidentified events early in the metastatic process (e.g. cell detachment, invasion, intravasation), and these aspects are now being investigated.
growth and with DNA cytophotometric analysis. In 6 cases of surgical resection of adenocarcinoma (3) or squamous carcinoma (3) of the oesophagus, specimens of tumour and macroscopically normal mucosa were cultured in vitro for 28 days. The extent of growth was correlated with results from sample biopsies submitted for histopathological examination. DNA cytophotometry was also studied using a single cell scanning microdensitometer. Biopsies of oesophageal and gastric mucosa from endoscopically normal patients were used to determine the normal diploid DNA content.
The study showed no correlation between normal or tumour cell growth in vitro and histological tumour We have developed an assay for Chinese hamster ovary cell viability that is based on the ability to multinucleate in the presence of the fungal metabolite cytochalasin B (CB) following exposure to radiation or to cytotoxic drugs. The degree of multinucleation achieved can be assessed after a given incubation period in CB either by a count of nuclei/cell or by measurement of the cellular DNA content. The method is intended to permit estimation of the survival of DNA synthesis in situations where cells cannot be fully monodispersed. Using a flow-cytometric method to find the cellular DNA content and to enumerate the absolute number of cells per culture, we have investigated the effect of cell density and glucose concentration on the cellular DNA content achieved after 50h incubation in the presence of CB. Above densities of -80,000 cells cm2 the proportion of seeded cells accumulating at least 3 times the DNA content of untreated GI cells is reduced, though the effect on the measured survival following 20Gy irradiation is small. The proportion of cells exceeding a DNA content of 3 x GI is sensitive to the concentration of glucose in the incubation medium. We postulate that the reduction in the cellular surface area/volume ratio that may occur as cultures become dense limits the acquisition of medium energy sources.
We have also investigated the shape of survival curves following irradiation or drug exposure. The survival of cells able to exceed a DNA content of 3 x GI after 50 h in CB seems to decrease exponentially with dose. Generally, survival is markedly greater than the corresponding clonogenic survival.
